Pliant Therapeutics Inc

NASDAQ:PLRXUnited States

ir@pliantrx.com
Pliant Therapeutics, Inc. Condensed Statements of Operations (Unaudited) (In thousands, except number of shares and per share amounts) Three Months Ended September 30, 2024 2023 -------------- ------------- Revenue $ -- $ -- Operating expenses: Research and development (47,754) (32,339) General and administrative (14,260) (15,346) -------------- ------------- Total operating expenses (62,014) (47,685) -------------- ------------- Loss from operations (62,014) (47,685) Interest and other income (expense), net 5,128 6,515 Interest expense (877) (317) -------------- ------------- Net loss $ (57,763) $ (41,487) ============== ============= Net loss per share - basic and diluted $ (0.95) $ (0.70) ============== ============= Shares used in computing net loss per share - basic and diluted 60,730,935 59,688,451 ============== ============= Pliant Therapeutics, Inc. Condensed Balance Sheets (Unaudited) (In thousands) September 30, December 31, 2024 2023 --------------- ---------------- Assets Current assets Cash and cash equivalents $ 79,616 $ 63,234 Short-term investments 324,897 431,011 Prepaid expenses and other current assets 5,518 11,257 ---------- --------- Total current assets 410,031 505,502 Property and equipment, net 5,671 3,567 Operating lease right-of-use assets 28,054 1,211 Restricted cash 1,482 1,482 Other non-current assets 427 392 ---------- --------- Total assets $ 445,665 $ 512,154 ========== ========= Liabilities and stockholders' equity Current liabilities Accounts payable $ 6,890 $ 4,531 Accrued research and development 23,025 12,456 Accrued liabilities 9,715 10,219 Operating lease liabilities, current 322 1,318 ---------- --------- Total current liabilities 39,952 28,524 Operating lease liabilities, non-current 29,752 -- Long-term debt 30,139 10,054 ---------- --------- Total liabilities 99,843 38,578 Stockholders' equity Preferred stock -- -- Common stock 6 6 Additional paid-in capital 1,005,288 972,973 Accumulated deficit (660,320) (499,748) Accumulated other comprehensive gain 848 345 ---------- --------- Total stockholders' equity 345,822 473,576 ---------- --------- Total liabilities and stockholders' equity $ 445,665 $ 512,154 ========== =========